Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001682:Biological Availability; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004311:Double-Blind Method; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008252:Macaca fascicularis; D008297:Male; D063065:Organophosphonates; D011485:Protein Binding; D016032:Randomized Controlled Trials as Topic; D012661:Semen / Q000821:virology
D019380:Anti-HIV Agents; D015507:Drugs, Investigational; D063065:Organophosphonates; D000225:Adenine; C106812:adefovir dipivoxil